Please Note: This trial is no longer enrolling new participants
A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients with Locally Advanced or Metastatic Solid Tumors
| Protocol No. | CTO-DAY301-001 | Scope | Local |
|---|---|---|---|
| Principal Investigator | Greg Durm | Treatment Type | Treatment |
| Age Group | Adult | Phase | Phase I |
